Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Publication|Articles|April 1, 2009
Oncology News International April 2009 Vol. 18 No. 4
Advertisement
Cover Story
Optimal use of aromatase inhibitors comes into focus
Masters of hematology and oncology: David Alberts, MD
DEPARTMENTS
News & Analysis
Pharmaceutical mergers raise fears of treatment pipeline pruning
Prophylaxis fends off life-threatening invasive fungal infections
MR spectroscopy separates brain tumor recurrence from radiation necrosis
Medicare approves coverage of FDG-PET scans for 11 cancers
Cancer Care: Practice & Policy
Two major studies add fuel to fire of PSA controversy
Focus on Prostate Cancer
Evidence grows for value of high-field MRI in prostate cancer Rx
Most prognostic prostate cancer markers lack clinical utility
Focus on Colon Cancer
Minority groups protest CMS rejection of CT-based colon cancer screening
Focus on Hematology
Clear-cut evidence for routine use of ESA agents remains elusive
Advertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5